Current reports
8-K
Corporate Presentation 2Q 2024
14 May 24
8-K
Other Events
8 May 24
8-K
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
6 May 24
8-K
3 Agenda ▪ Business Update ▪ Our Research Strategy ▪ Our Platform ▪ Lead Candidates ▪ Forward Looking ▪ Closing Remarks ▪ Q&A
9 Apr 24
8-K
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
13 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
8-K
Departure of Directors or Certain Officers
29 Feb 24
8-K
Entry into a Material Definitive Agreement
24 Jan 24
8-K
Entry into a Material Definitive Agreement
19 Jan 24
8-K
Other Events
4 Jan 24
Registration and prospectus
424B5
Prospectus supplement for primary offering
7 May 24
424B5
Prospectus supplement for primary offering
6 May 24
424B3
Prospectus supplement
15 Mar 24
424B3
Prospectus supplement
15 Mar 24
POS AM
Prospectus update (post-effective amendment)
13 Mar 24
POS AM
Prospectus update (post-effective amendment)
13 Mar 24
POS AM
Prospectus update (post-effective amendment)
13 Mar 24
S-8
Registration of securities for employees
18 Dec 23
S-8
Registration of securities for employees
4 Dec 23
SC TO-I/A
Issuer tender offer statement (amended)
5 Apr 23
Other
EFFECT
Notice of effectiveness
15 Mar 24
EFFECT
Notice of effectiveness
15 Mar 24
EFFECT
Notice of effectiveness
15 Mar 24
EFFECT
Notice of effectiveness
27 Mar 23
EFFECT
Notice of effectiveness
21 Mar 23
CORRESP
Correspondence with SEC
21 Mar 23
UPLOAD
Letter from SEC
21 Mar 23
CORRESP
Correspondence with SEC
16 Mar 23
UPLOAD
Letter from SEC
14 Mar 23
EFFECT
Notice of effectiveness
19 Sep 22
Ownership
3
HANS PETER WILD
6 Jun 24
3
Thomas Pfisterer
6 Jun 24
4
Jeremy Green
10 May 24
4
AMEET MALLIK
9 May 24
144
Notice of proposed sale of securities
7 May 24
SC 13G
Oaktree Capital Group Holdings GP, LLC
3 May 24
SC 13D/A
AUVEN THERAPEUTICS HOLDINGS LP
25 Apr 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
Prosight Management, LP
13 Feb 24
SC 13G/A
ASTRAZENECA PLC
12 Feb 24